Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$4.8B
172M shares
52-week range
$19.69 – $30.96
69% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
4.2
EV / FCF (TTM)
25.4
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
www.acadia.comNo one on the platform currently holds ACAD.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,724,196 | $38.4M |
| Bridgewater Associatesas of 2026-03-31 | 141,812 | $3.2M |
No one on the platform has traded ACAD yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 26.8% | — | — | — | ||
| Rev. Growth % | 11.9% | 19.4% | ||||
| Profit Margin % | 36.5% | -4.9% | -206.5% | |||
| Free Cash Flow Margin % | 9.8% | -5.0% | -162.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +24.9% on the P/E track.
At today's price, your expected annual return is +31.9% on the P/E track.
At today's price, your expected annual return is +39.2% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.3B | +17.8% | $0.61 | $0.46–$0.85 | 44.8× | 14 |
| 2027 | $1.4B | +12.6% | $0.91 | $0.46–$1.75 | 30.2× | 13 |
| 2028 | $1.6B | +12.7% | $1.55 | $0.88–$3.01 | 17.7× | 14 |
| 2029 | $1.7B | +6.5% | $1.86 | $1.76–$2.02 | 14.8× | 7 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $0.07 | $0.18 | +164.1% |
| 2026-05-06 | $0.04 | $0.02 | -50.0% |
| 2026-02-25 | $0.14 | $1.60 | +1067.9% |
| 2025-11-05 | $0.14 | $0.42 | +200.0% |
| 2025-08-06 | $0.14 | $0.16 | +14.3% |
| 2025-05-07 | $0.10 | $0.11 | +10.0% |
| 2025-02-26 | $0.19 | $0.86 | +352.6% |
| 2024-11-06 | $0.14 |
| $0.20 |
| +42.9% |
| $3.5B |
| — |
| IMVTImmunovant, Inc. | $37.66 | +0.80% | $7.8B | — |
| LGNDLigand Pharmaceuticals Incorporated | $280.65 | -1.34% | $5.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ACAD This is beyond ridiculous unless there’s a leak that the trial data is yet another failure. Of course the thugs could be pushing it down to add and make a quick return of its good. Either way way it’s BS.
View on StockTwits ↗$ACAD This is Fkd up. Major catalyst on the way and cant hold $30. Wanted us $32 or more when the news hits. Better be stellar and get the scum out of here.
View on StockTwits ↗
Canaccord Genuity reiterated $ACAD Buy-$36 $BMY $AXSM CGTX LLY BIIB PFE ABBV JNJ OTSKY Here's what Canaccord Genuity said in its note to investors: https://x.com/Quantumup1/status/2095465482170028261?s=20
View on StockTwits ↗
$ACAD Q2 2026: revenue $307.96M, net income $31.5M. DAYBUE (Rett syndrome) $125M in net sales; NUPLAZID (Parkinson's psychosis) $183M. Raised FY26 revenue guidance to $1.24B-$1.30B. Stock up ~11.9% in the month through Aug. 28, hit intramonth high of $30.96 before consolidating near $29. Watch patient starts, script trends, payer coverage, and remlifanserin pipeline data as the next catalysts. $ACAD #Biotech #Pharma https://prismmarketview.com/acadia-pharmaceuticals-builds-growth-momentum-as-daybue-and-nuplazid-sales-rise/
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.